Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 18 | 2023 | 1021 | 3.560 |
Why?
|
| Brain Ischemia | 4 | 2020 | 299 | 1.290 |
Why?
|
| Endocarditis | 2 | 2019 | 32 | 1.260 |
Why?
|
| Anticoagulants | 4 | 2023 | 550 | 0.870 |
Why?
|
| Neurology | 1 | 2023 | 84 | 0.830 |
Why?
|
| Cerebral Arteries | 1 | 2022 | 55 | 0.780 |
Why?
|
| Thrombophilia | 1 | 2021 | 67 | 0.720 |
Why?
|
| Neurologists | 1 | 2020 | 18 | 0.720 |
Why?
|
| Carotid Artery, Internal, Dissection | 1 | 2020 | 6 | 0.720 |
Why?
|
| Vertebral Artery Dissection | 1 | 2020 | 18 | 0.710 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 87 | 0.700 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2020 | 45 | 0.690 |
Why?
|
| Thrombectomy | 2 | 2022 | 51 | 0.660 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 3 | 2023 | 9 | 0.640 |
Why?
|
| Cerebral Angiography | 1 | 2018 | 109 | 0.610 |
Why?
|
| Fibrinolytic Agents | 1 | 2020 | 234 | 0.600 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 76 | 0.590 |
Why?
|
| Computed Tomography Angiography | 1 | 2018 | 97 | 0.580 |
Why?
|
| Ischemic Attack, Transient | 3 | 2023 | 62 | 0.560 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 322 | 0.540 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2018 | 219 | 0.540 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 221 | 0.540 |
Why?
|
| Pregnancy Complications | 1 | 2020 | 429 | 0.520 |
Why?
|
| Internship and Residency | 1 | 2023 | 926 | 0.470 |
Why?
|
| Hospitalization | 3 | 2020 | 1749 | 0.460 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 1177 | 0.400 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 413 | 0.390 |
Why?
|
| Brain | 2 | 2023 | 2371 | 0.390 |
Why?
|
| Venous Thrombosis | 2 | 2022 | 140 | 0.360 |
Why?
|
| Intracranial Embolism | 2 | 2019 | 29 | 0.310 |
Why?
|
| Thrombolytic Therapy | 2 | 2019 | 117 | 0.290 |
Why?
|
| Smoking Cessation | 2 | 2023 | 374 | 0.290 |
Why?
|
| Humans | 24 | 2023 | 114599 | 0.280 |
Why?
|
| Aged, 80 and over | 8 | 2023 | 6344 | 0.260 |
Why?
|
| Young Adult | 5 | 2023 | 10452 | 0.260 |
Why?
|
| Smoking | 3 | 2023 | 1380 | 0.240 |
Why?
|
| Vasospasm, Intracranial | 1 | 2023 | 17 | 0.220 |
Why?
|
| Noma | 1 | 2023 | 2 | 0.220 |
Why?
|
| Cerebrovascular Disorders | 1 | 2023 | 82 | 0.210 |
Why?
|
| Status Epilepticus | 1 | 2023 | 32 | 0.210 |
Why?
|
| Renal Colic | 1 | 2022 | 3 | 0.210 |
Why?
|
| Cerebral Veins | 1 | 2022 | 15 | 0.200 |
Why?
|
| Aged | 11 | 2023 | 19056 | 0.200 |
Why?
|
| Dabigatran | 1 | 2022 | 22 | 0.200 |
Why?
|
| Intracranial Thrombosis | 1 | 2022 | 17 | 0.200 |
Why?
|
| Female | 16 | 2023 | 59446 | 0.200 |
Why?
|
| Administration, Oral | 2 | 2022 | 728 | 0.190 |
Why?
|
| Risk Factors | 8 | 2023 | 8624 | 0.190 |
Why?
|
| Arteries | 1 | 2023 | 247 | 0.190 |
Why?
|
| Warfarin | 1 | 2022 | 135 | 0.190 |
Why?
|
| Fellowships and Scholarships | 1 | 2023 | 227 | 0.180 |
Why?
|
| Middle Aged | 11 | 2023 | 26705 | 0.180 |
Why?
|
| Retrospective Studies | 10 | 2023 | 12541 | 0.180 |
Why?
|
| Drug Substitution | 1 | 2020 | 46 | 0.180 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2020 | 11 | 0.170 |
Why?
|
| Mobile Health Units | 1 | 2019 | 18 | 0.170 |
Why?
|
| Adult | 8 | 2023 | 30514 | 0.170 |
Why?
|
| Ambulances | 1 | 2019 | 50 | 0.170 |
Why?
|
| Drug Utilization | 1 | 2020 | 167 | 0.170 |
Why?
|
| Thrombosis | 1 | 2022 | 298 | 0.160 |
Why?
|
| Pregnant Women | 1 | 2020 | 131 | 0.160 |
Why?
|
| Treatment Outcome | 4 | 2022 | 9084 | 0.160 |
Why?
|
| Registries | 4 | 2019 | 1767 | 0.160 |
Why?
|
| Pregnancy | 2 | 2020 | 5516 | 0.160 |
Why?
|
| United States | 5 | 2022 | 12167 | 0.160 |
Why?
|
| Endovascular Procedures | 1 | 2022 | 269 | 0.160 |
Why?
|
| Health Care Surveys | 1 | 2020 | 539 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 147 | 0.150 |
Why?
|
| Geography | 1 | 2019 | 177 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 544 | 0.150 |
Why?
|
| Troponin | 1 | 2017 | 44 | 0.150 |
Why?
|
| Sex Factors | 2 | 2020 | 1715 | 0.140 |
Why?
|
| Health Surveys | 1 | 2019 | 443 | 0.140 |
Why?
|
| Adolescent | 3 | 2020 | 17827 | 0.140 |
Why?
|
| Survivors | 1 | 2020 | 411 | 0.140 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2020 | 401 | 0.140 |
Why?
|
| Stroke Volume | 1 | 2019 | 504 | 0.130 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 467 | 0.130 |
Why?
|
| Medication Adherence | 1 | 2020 | 536 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2019 | 358 | 0.130 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2017 | 225 | 0.120 |
Why?
|
| Male | 11 | 2023 | 55534 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 1796 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2020 | 3001 | 0.110 |
Why?
|
| Myocardial Infarction | 1 | 2020 | 927 | 0.110 |
Why?
|
| Incidence | 1 | 2019 | 2311 | 0.100 |
Why?
|
| Depression | 1 | 2020 | 1132 | 0.100 |
Why?
|
| Age Factors | 1 | 2019 | 2893 | 0.100 |
Why?
|
| New York City | 2 | 2019 | 70 | 0.080 |
Why?
|
| Seizures | 2 | 2023 | 340 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2020 | 953 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 1213 | 0.070 |
Why?
|
| Medicare | 2 | 2020 | 665 | 0.060 |
Why?
|
| Logistic Models | 2 | 2020 | 1839 | 0.060 |
Why?
|
| Middle Cerebral Artery | 1 | 2023 | 37 | 0.050 |
Why?
|
| Diagnostic Errors | 1 | 2023 | 149 | 0.050 |
Why?
|
| Vasoconstriction | 1 | 2023 | 177 | 0.050 |
Why?
|
| Child | 1 | 2020 | 18401 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2023 | 4894 | 0.040 |
Why?
|
| Varenicline | 1 | 2020 | 22 | 0.040 |
Why?
|
| Bupropion | 1 | 2020 | 39 | 0.040 |
Why?
|
| Urban Health | 1 | 2019 | 73 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 90 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 4404 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2020 | 224 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 124 | 0.030 |
Why?
|
| Cerebral Hemorrhage | 1 | 2017 | 96 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 493 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2017 | 807 | 0.030 |
Why?
|
| Patient Safety | 1 | 2017 | 277 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1430 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 4411 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2019 | 2967 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2019 | 6214 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 3405 | 0.020 |
Why?
|